Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism
8.5
来源：
Nature
关键字：
siRNA
发布时间：
2025-12-08 11:33
摘要：
Lysophosphatidylethanolamine 18:1 (LPE18:1) has been identified as a key driver of clear cell renal cell carcinoma (ccRCC) progression, linking lipid metabolism reprogramming to tumor aggressiveness. The study reveals that LPE18:1 stabilizes SIRT6 through CAPZA1, enhancing lipid accumulation and promoting tumor growth. High levels of CAPZA1 and SIRT6 correlate with advanced tumor stages and poor prognosis, suggesting their potential as therapeutic targets. This research underscores the importance of lipid metabolism in ccRCC and highlights the CAPZA1/SIRT6 axis as a promising area for future therapeutic strategies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.8
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
LPE18:1 upregulates CAPZA1, promoting SIRT6 stabilization and lipid accumulation.
High levels of CAPZA1 and SIRT6 correlate with poor prognosis in ccRCC.
Targeting the CAPZA1/SIRT6 axis significantly suppresses ccRCC cell growth.
真实性检查
否
AI评分总结
Lysophosphatidylethanolamine 18:1 (LPE18:1) has been identified as a key driver of clear cell renal cell carcinoma (ccRCC) progression, linking lipid metabolism reprogramming to tumor aggressiveness. The study reveals that LPE18:1 stabilizes SIRT6 through CAPZA1, enhancing lipid accumulation and promoting tumor growth. High levels of CAPZA1 and SIRT6 correlate with advanced tumor stages and poor prognosis, suggesting their potential as therapeutic targets. This research underscores the importance of lipid metabolism in ccRCC and highlights the CAPZA1/SIRT6 axis as a promising area for future therapeutic strategies.